In this issue:
Long-acting intramuscular cabotegravir and rilpivirine
Protease inhibitor monotherapy vs lamivudine dual therapy
On-demand PrEP for HIV
Ageing and neurocognitive function by stage of HIV infection
Dolutegravir/abacavir/ lamivudine vs current ART
CD4:CD8 ratio and CD8 count as prognostic markers for mortality
Changes in liver steatosis after switching from efavirenz to raltegravir
BMD recovery after tenofovir discontinuation
Gene polymorphisms, dolutegravir concentrations and neuropsychiatric events
Pre-treatment INSTI resistance
Please login below to download this issue (PDF)